-
1 Comment
SI-BONE, Inc is currently in a long term uptrend where the price is trading 0.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.2.
SI-BONE, Inc's total revenue rose by 11.8% to $22M since the same quarter in the previous year.
Its net income has increased by 1.3% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 11.6% to $-9M since the same quarter in the previous year.
Based on the above factors, SI-BONE, Inc gets an overall score of 5/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US8257041090 |
Sector | Healthcare |
Industry | Medical Devices |
Market Cap | 611M |
---|---|
Beta | 1.02 |
PE Ratio | None |
Target Price | 24.4444 |
Dividend Yield | None |
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SIBN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025